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(range:15.1mm/h (France)-21.0mm/h (Italy)) and CRP (range:5.6mg/dl (Spain)-
12.5mg/dl (UK)). Current disease severity per physician-judgment 
(mild:moderate:severe) in 5EU were: UK-68%:22%:10%, Germany-57%:39%:5%, 
France-46%:47%:7%, Italy-64%:34%:2%, Spain-69%:27%:4%. Among patients with 
available data, current HAQ (range: 0.7(France)-1.5(Germany)), BASDAI 
(range:3.0(Spain)-3.4(UK)), 100mmVAS (range:19.0(France)-31.4(UK)) and Swollen 
Joint Count (range:0.5(France)-(3.7(UK)) differed within 5EU. Among patients with 
available data, response to current biologic per ASAS criteria were 
(%ASAS20:%ASAS40:ASAS5/6:%ASAS partial-remission): UK-12%:6%:0%:4%, 
Germany-20%:9%:9%:11%, France-13%:7%:7%:11%, Italy-30%:17%:13%:18%, Spain-
19%:13%:5%:13%. CONCLUSIONS: Among AS patients receiving their first 
biologic, disease severity differed within 5EU, with patients in the UK with 
relatively higher burden and poorer treatment response. Impact of specific 
biologic treatments on the observed patterns warrants further scrutiny.  
 
PMS10  
COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH 
PSORIATIC ARTHRITIS (PSA) RECEIVING THEIR FIRST BIOLOGIC IN UK, 
GERMANY, FRANCE, ITALY AND SPAIN (5EU)  
Narayanan S1, Lu Y2, Hutchings R2, Baskett A2 
1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK  
OBJECTIVES: To compare the disease status and outcomes of patients with PsA 
receiving their first biologic in 5EU. METHODS: A multi-country multi-center 
medical chart-review study of PsA patients was conducted among physicians 
(rheumatologists:97%) in hospitals and private practices to collect de-identified 
data on patients who were recently treated with a biologic as part of usual care. 
Physicians were screened for duration of practice (3-30 yrs) and patient volume 
(incl. >5PsA biologic patients/month) and recruited from a large panel to be 
geographically representative in each country. Eligible patient charts (>3) were 
randomly selected from a sample of prospective patients visiting each 
center/practice during the screening period. Physicians abstracted patient 
diagnosis, treatment patterns/dynamics and patient symptomatology/disease 
status/outcomes. RESULTS: In 1Q2012, 1099 eligible PsA patient charts were 
abstracted; 916 (83%) patients were on their first biologic (mean-age:48.1yrs, 
female:46%). Geographic distribution of patients were – UK:20%, Germany:18%, 
France:22%, Italy:21%, Spain:19%. Time-to-1st biologic from diagnosis 
(range:31month (Italy)-50month (UK)) and time-on-current biologic 
(range:19month (Italy)-24month (France)) differed within 5EU. The top-4 reasons 
for biologic treatment initiation across 5EU were ‘mechanism of action’, ‘improve 
signs/symptoms’, ‘preservation of structural damage’ and ‘positive personal 
experience’. Key lab measures documented were: ESR (range:18.6mm/h (France)-
25.2mm/h (Italy)) and CRP (range:6.3mg/dl (Spain)-14.5mg/dl (UK)). Current 
disease severity per physician-judgment (mild:moderate:severe) in 5EU were: 
UK-61%:25%:13%, Germany-57%:37%:6%, France-44%:46%:11%, Italy-56%:41%:2%, 
Spain-64%:33%:3%. Among patients with available data, current HAQ (range: 
0.7(Spain)-1.5(Germany)), BASDAI (range:2.7(Spain)-3.9(UK)), 100mmVAS 
(range:23.9(Spain)-31.4(UK)) and Swollen Joint Count (range:1.2(Spain)-(3.7(UK)) 
differed within 5EU. Among patients with available data, response to current 
biologic per ASAS criteria were (%ASAS20:%ASAS40:ASAS5/6:%ASAS partial-
remission): UK-8%:8%:0%:4%, Germany-18%:7%:9%:12%, France-11%:6%:6%:10%, 
Italy-29%:16%:12%:15%, Spain-13%:14%:9%:9%. CONCLUSIONS: Among PsA 
patients receiving their first biologic, disease severity and outcomes differed 
within 5EU, with patients in the UK with relatively higher burden and poorer 
treatment response. Impact of specific biologic treatments on the observed 
patterns warrants further scrutiny.  
 
PMS11  
META-ANALYSIS FOR EFFICACY OF ETANERCEPT FOR TREATMENT OF 
PSORIATIC ARTHRITIS  
Aggarwal S, Topaloglu H, Messenger M 
Novel Health Strategies, Bethesda, MD, USA  
OBJECTIVES: Psoriatic arthritis (PA) is an inflammatory disease affecting joints 
and connective tissues. The anti-tumor necrosis factor (TNF) biologics are 
increasingly being used in patients who have failed traditional disease-
modifying antirheumatic drugs. Etanercept has shown efficacy in treatment of 
PA. The objective of this study was to conduct meta-analysis and present total 
evidence for etanercept in treatment of PA. METHODS: For this meta-analysis we 
included randomized controlled trials (RCTs)evaluating etanercept for the 
treatment of PS. RCTs studying adult populations with active and progressive PA 
with an inadequate response to previous DMARD therapy were eligible. Trials 
conducted among PA populations with prior experience with anti-TNF agents, 
including an inadequate response, were excluded. A systematic literature search 
for Etanercept trials was undertaken for the databases Pubmed, Embase, Biosis, 
Google Scholar, and Cochrane. Data was collected for the study size, 
interventions, year, and the three outcomes HAQ, PASI and PsARC. For meta-
analysis, random effects and fixed effects models were used to obtain 
cumulative statistics. RESULTS: Two RCTs with a total of 131 patients were 
identified. The pooled response rates for Etanercept for PsARC were 75% (95% CI 
60%-90%), for HAQ were 59% (95% CI 46%-72%), and for PASI were 24% (95% CI 
13%-34%). The pooled response rates for placebo for PsARC were 30% (95% CI 
26%-35%), for HAQ were 5% (95% CI 1%-9%), and for PASI were 3% (95% CI 0%-7%). 
For PsARC the cumulative relative risk with Etanercept versus placebo was 0.40 
(95% CI 33%-48%). For HAQ, the cumulative relative risk with Etanercept versus 
placebo was 0.08 (95% CI 5%-12%). For PASI, the cumulative relative risk with 
Etanercept versus placebo was 0.14 (95% CI 8%-20%). CONCLUSIONS: Meta-
analysis shows Etanercept offers patients with psoriatic arthritis an effective 
therapeutic option for control of their disease.  
PMS12  
STRUCTURING CRITERIA IN MULTI-CRITERIA DECISION MODELS FOR 
BENEFIT/RISK ASSESSMENT OF BIOLOGICS IN JUVENILE ARTHRITIS  
Satiti M1, IJzerman MJ1, Boere-Boonekamp M1, Bridges JFP2 
1University of Twente, Enschede, The Netherlands, 2Johns Hopkins Bloomberg School of Public 
Health, Baltimore, MD, USA  
OBJECTIVES: Multi-criteria decision analysis (MCDA) is a technique which is 
proposed for quantitative benefit/risk assessment. MCDA structures benefits and 
risks in a decision or value tree, either by forming hierarchical clusters of 
benefits and risks separately or by placing both benefits and risks on the same 
level allowing direct comparison of all benefits and risks (non-hierarchical). The 
objective of this study was to compare two approaches for structuring decision 
trees and to evaluate the rank-order of three TNF– inhibitors for Methotrexate 
type of Juvenile Idiopathic Arthritis (JIA). METHODS: The alternatives selected for 
evaluation were Etanercept, Infliximab and Adalimumab. Six criteria were 
identified for evaluation, including improvement in pain, improvement in social 
function, Methotrexate (MTX) discontinuation, administration reaction, serious 
infection and cancer. The criteria were structured both non–hierarchically and 
hierarchically. Two different questionnaires were developed and randomized to 
42 physicians in three hospitals. Weight elicitation was performed using the 
Analytic Hierarchy Process. RESULTS: In hierarchical structures, the criterion 
weights were more steep and the range between most and least important 
criterion was larger than in non-hierarchical structures. Risks were considered 
more important (aggregated wrisk=0.35) in an non-hierarchical structure than in 
an hierarchical structure (wrisk=0.20). Applying the performance weights for three 
TNF-a inhibitors showed that there is a different rank-order of drugs being 
considered. The weights elicited from non–hierarchical questionnaire showed 
Etanercept to be most preferred. Yet, Adalimumab was most preferred if a 
hierarchical structure was used. The non–hierarchical questionnaire could be 
transformed to a hierarchical structure after which a similar rank-order of drugs 
was found as in the hierarchical structure. CONCLUSIONS: The rank order of the 
alternatives indeed changes when the criteria were structured differently 
regardless where the criteria weights were obtained from similar or different 
group of participants. Policy implications need to be explored.  
 
PMS13  
ASSESSING THE GEOGRAPHIC AND DEMOGRAPHIC VARIATION ASSOCIATED 
WITH PSORIATIC ARTHRITIS PREVALENCE IN THE VETERAN POPULATION IN 
THE UNITED STATES  
Wang L1, Huang A1, Baser O2 
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research/The University of Michigan, 
Ann Arbor, MI, USA  
OBJECTIVES: To study the relationship between psoriatic arthritis (PsA) 
prevalence and geographic variation and demographic characteristics in the U.S. 
veteran population. METHODS: Using the Veterans Health Administration (VHA) 
Medical SAS Datasets from October 1, 2005 to May 31, 2012, a retrospective 
database analysis was performed. All U.S. veteran beneficiaries diagnosed with 
PsA were identified using International Classification of Disease 9th Revision 
Clinical Modification (ICD-9-CM) diagnosis code 696.0. All patients with medical 
benefit enrollment in 2011 were included in the study. Descriptive statistics were 
calculated as means±standard deviation (SD) and percentages to measure age, 
race and other related factors in the sample. RESULTS: A total of 22,102 veterans 
were diagnosed with PsA during 2011. The state of Vermont had the highest 
prevalence rate (0.29%), followed by New Hampshire (0.23%), and Maine (0.23%). 
All other states were observed with prevalence rates lower than 0.2%. 
Washington D.C. had only three cases of the disease, which translated into 0.02% 
of prevalence. Patients age 55-64 were most likely to be diagnosed with PsA 
(0.15%). Prevalence was lower by 0.05% for patients age 35-54 and 65+ (0.10%). 
Younger patients were less likely to be diagnosed with the disease (<0.05%). PsA 
diagnoses also varied by race: Non-Hispanic White (0.14%), Hispanic (0.12%), 
Non-Hispanic Black (0.03%), and other races (0.08%). CONCLUSIONS: PsA was 
unevenly distributed across the United States when measured by age group and 
race. Geographic variation was also related to disease occurrence. These factors 
should be taken into consideration for further studies.  
 
PMS14  
ANNUAL MORTALITY IN A LARGE PREVALENCE-BASED SAMPLE OF UNITED 
STATES RHEUMATOID ARTHRITIS PATIENTS  
Palmer LA, Farr A, Johnston SS 
Truven Health Analytics, Washington, DC, USA  
OBJECTIVES: Studies estimating mortality rates in United States rheumatoid 
arthritis (RA) patients have largely been based upon registry or single-center 
populations numbering in the hundreds or few thousands of RA patients, which 
limits the generalizability of their findings. The objective of this study was to 
describe annual mortality in a large prevalence-based sample of U.S. RA patients. 
METHODS: This was a retrospective study based on mortality data obtained from 
the Social Security Administration (SSA) linked to approximately 15 million 
individuals present in the Truven Health MarketScan® Commercial and Medicare 
Supplemental administrative claims databases. The SSA data currently include 
information on whether individuals were living or had died (including date of 
death) as of October 31, 2012. To maximize generalizability, this study used a 
prevalence-based sampling technique whereby RA patients representing a broad 
spectrum of disease durations and severity were selected. To that end, patients 
aged 18+ years were selected for study if they were continuously enrolled in 
insurance benefits throughout calendar year 2010 and during this time period 
had at ≥1 medical claim with an ICD-9-CM code for RA (714.0x). Claims that may 
have represented efforts to ‘rule out’ the presence of RA were excluded from 
consideration. The study outcome was age/sex-specific mortality rates in 2011. 
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RESULTS: A total of 54,341 RA patients met the study inclusion criteria; mean 
age 59 years, 67% female. Of these patients, a total of 1033 (1.9%) died in 2011. 
Age and sex-specific mortality rates were: male/age 18-35 (0/532;0.0%); 
female/age 18-35 (1/2391;0.0%%); male/age 36-55 (16/4889 0.3%); female/age 36-55 
(27/13462;0.2%); male/age 56-75 (191/9455;2.0%); female/age 56-75 
(190/15891;1.2%); male/age 76+ (271/3128;8.5%); female/age 76+ (337/4593;7.3%). 
CONCLUSIONS: This is the first study to describe annual mortality in a large 
prevalence-based sample of U.S. RA patients. Additional analyses to examine 
risk factors and suspected causes of mortality are warranted.  
 
PMS15  
EVIDENCE ON SAFETY OF METAL-ON-METAL HIP RESURFACING 
ARTHROPLASTY  
Sehatzadeh S, Levin L 
Health Quality Ontario, Toronto, ON, Canada  
OBJECTIVES: Metal-on-metal hip resurfacing arthroplasty (MOM HRA) is an 
alternative to total hip arthroplasty in young patients. There are multiple reports 
indicating higher rate of revision for MOM HRA and health regulators are 
currently scrutinizing failure rates and safety of these implants. The revision 
rates of implants licensed in Canada were compared with the benchmark set by 
the National Institute of Clinical Excellence (NICE), i.e., a revision rate of 10% or 
less at 10 years. METHODS: Studies published from January 1, 2009 to February 
13, 2012 were included. The literature was examined to identify articles 
discussing the biological effects of metal implants. RESULTS: The revision rates 
for MOM HRA with BHR, ConservePlus, and Cormet implants met NICE criteria. 
Revision rate for ReCap implant was 2% at a mean follow-up of 2.9 years. Two 
studies reported revision rates of 3.7% and 11% for Durum implant at a mean 
follow-up of 5 years. The ASR implant had a revision rate of 10.9% at 5 years. In 
addition to implant design, several factors including selection of patients and 
skills of the surgeons in proper positioning of the implant that helps to reduce 
rate of wear contributed to the success of the procedure. The consensus among 
orthopedic surgeons is that the ideal patients for MOM HRA are young male 
patients with end-stage hip osteoarthritis, good bone quality, and proper 
anatomy around the affected joint. There are reports of high levels of metal ions 
in the blood and urine of patients with these implants. Production of metal 
debris due to friction between the 2 components may result in inflammation in 
the joint or development of a soft tissue mass leading to implant failure. 
CONCLUSIONS: MOM HRA can be beneficial for appropriately selected patients, 
provided the surgeon has the surgical skills required for performing this 
procedure.  
 
MUSCULAR-SKELETAL DISORDERS – Cost Studies 
 
PMS16  
BUDGET IMPACT ANALYSIS OF OSTEOPOROSIS DRUG THERAPY 
REIMBURSEMENT CRITERIA UPDATES IN KOREA  
Park SY1, Kim Y2, Hyun MK2, Park JY2, Ahn J2 
1SKKU, Suwon, South Korea, 2National Evidence-based Healthcare Collaborating Agency (NECA), 
Seoul, South Korea  
Prior to 2012, the reimbursement criteria for osteoporosis medications has been 
criticized for its strict BMD indication and 6-month coverage period in Korea. The 
cost estimate of expanding coverage to clinically recommended level was 130 
billion KRW. OBJECTIVES: To suggest a better estimate of budget impacts for 
osteoporosis drug therapy in Korea METHODS: A 5-year semi-annual Markov 
model focusing on the fracture-preventing effects of osteoporosis medications 
was constructed. Fracture-preventing effects of osteoporosis drugs were 
extracted from previous systematic reviews and the HIRA’s national health 
insurance claims database from 2006 to 2008 was used to estimate the 
probabilities and costs for modeling. Mortality rate at each stage was estimated 
from the literature and the Statistics Korea. The Korean National Health and 
Nutrition Examination Survey data and Korean FRAX tool were utilized to 
calculate the population at each stage. The scenarios of reimbursement criteria 
expansion were composed of BMD T-score, coverage period, and including high-
fracture-risk patients with osteopenia. RESULTS: Reimbursement coverage 
expansion is expected to increase budget input, but the increase gradually 
decrease over time. If the reimbursement criteria is expanded to T-score≤-2.5, 
coverage period increased to 1 year, but excluding high-fracture-risk osteopenia, 
then about 450 billion KRW is required for osteoporosis drug acquisition for 5 
years along with 120 billion KRW saving for fracture treatment costs compared to 
the existing criteria. Considering both expansion costs and fracture costs, the 
reduction in fracture costs partially offsets the expanded coverage of 
osteoporosis drugs. In summary, 87 billion KRW was estimated for the first year 
budget impact and it gradually decreases to about 50 billion KRW in the fifth 
year. CONCLUSIONS: This budget impact analysis considering both increase in 
osteoporosis drug cost and saved fracture cost shows the total health insurance 
budget impact is lower than the previously suggested amount.  
 
PMS17  
COST PER TREATED PATIENT FOR BIOLOGICS IN RHEUMATOID ARTHRITIS, 
PSORIATIC ARTHRITIS, PSORIASIS AND ANKYLOSING SPONDYLITIS USING 
CLAIMS DATA  
Bonafede MM1, Joseph G2, Princic N1, Harrison DJ2 
1Truven Health Analytics, Cambridge, MA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA  
OBJECTIVES: To estimate annual cost per treated patient for etanercept, 
adalimumab, infliximab, abatacept, rituximab, golimumab, certolizumab, and 
ustekinumab in rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, and 
ankylosing spondylitis in a US claims population. METHODS: MarketScan 
Commercial Database was used to identify patients (18-63 years) with ≥1 claim 
for a biologic of interest between January 1, 2008 and December 31, 2010 
preceded by ≥6-months of enrollment and a diagnosis of RA, psoriasis, psoriatic 
arthritis, or ankylosing spondylitis. The first drug claim meeting these criteria 
defined the index date and biologic. “Continuing” patients had ≥1 claim for the 
same biologic before their index date, “New” patients did not. Patients were 
required to be continuously enrolled for 1-year following the index claim. 
Patients with Crohn’s disease, or ulcerative colitis pre-index were excluded since 
not all biologics are approved for these indications. Mean monthly dose and total 
dose of other biologics after discontinuation of their index biologic was 
calculated for the 12-months after index. Wholesale acquisition costs and the 
Medicare Physician Fee Schedule were applied to the mean monthly dose and 
related drug administration to calculate cost per treated patient. RESULTS: A 
total of 69,349 patients were included, 92.3% received etanercept (32,298), 
adalimumab (20,582), or infliximab (11,157). Patient characteristics were similar 
across groups; mean age 47.8 years (SD 10.2), 63% female. Mean annual cost per 
treated patient pooled across indications was $20,508 etanercept, $21,179 
adalimumab, and $23,446 infliximab. Cost per treated patient in RA (55% of 
patients) ranged from $18,888 abatacept to $22,158 infliximab and in psoriasis, 
(20% of patients), from $21,034 adalimumab to $31,478 ustekinumab. 
CONCLUSIONS: Based on drug utilization from this US managed care population, 
of agents approved for all indications, etanercept had the lowest cost per treated 
patient across all indications. In RA, abatacept had the lowest cost, whereas 
infliximab had the highest.  
 
PMS18  
COST PER TREATED PATIENT FOR BIOLOGICS ACROSS ADULT INDICATIONS 
USING CLAIMS DATA  
Schabert VF1, Korn J2, Bilir P3, DeKoven M1, Harrison DJ4, Joseph G4 
1IMS Health Consulting Group, Alexandria, VA, USA, 2IMS Health, Waltham, MA, USA, 3IMS 
Health Consulting Group, Redwood City, CA, USA, 4Amgen, Inc., Thousand Oaks, CA, USA  
OBJECTIVES: To estimate annual biologic cost per treated patient in rheumatoid 
arthritis (RA), plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis 
using drug utilization from US managed care. METHODS: The IMS LifeLink 
Health Plan Claims Database was used to identify adults (18-63 years) with a 
claim for etanercept, adalimumab, infliximab, abatacept, rituximab, golimumab, 
certolizumab, or ustekinumab between January 1, 2008 and December 31, 2010 
preceded by ≥180-days of enrollment. Patients had to have a qualifying diagnosis 
between 180 days before and 30 days after index and be enrolled for ≥360 days 
post-index. The first biologic claim meeting these criteria defined the index date. 
Patients with pre-index Crohn’s disease, ulcerative colitis, non-Hodgkins 
lymphoma, or chronic lymphocytic lymphoma were excluded. Annual cost per 
treated patient equaled total dose for the index biologic and biologics taken after 
discontinuation of the index biologic multiplied by October 2012 WAC, plus 
number of administrations multiplied by the 2012 Medicare Physician Fee 
Schedule costs. RESULTS: Of 35,525 included patients; 92.7% received etanercept 
(n=16,704), adalimumab (n=10,154), or infliximab (n=6,056). Most patients (63%) 
were female, mean age 48.9 years and treated for RA (56%). Pooled across 
indications, cost per treated patient for agents approved for all indications was 
$20,284 for etanercept, $20,010 for adalimumab, and $22,795 for infliximab. Cost 
per treated patient in RA was $19,251 for etanercept, $20,387 for adalimumab, 
$21,585 for infliximab. The range in other agents was from $16,286 for 
golimumab (n=120) to $19,710 for certolizumab (n=101). In psoriasis, cost per 
treated patient ranged from $20,261 for adalimumab (n=1,874), to $34,951for 
ustekinumab (n=116). The costs in other groups were similar to those in RA. 
CONCLUSIONS: Of agents approved for all indications, infliximab, which is 
infused, had higher costs than adalimumab or etanercept which are self-
injected. Although some new agents had lower costs in RA, sample size for these 
agents was limited.  
 
PMS19  
INPATIENT HOSPITAL COSTS AND LENGTH OF STAY FOR THE TREATMENT OF 
OSTEOPOROSIS FRACTURES IN CHINA  
Li J1, Burge RT2, Ye WW3, Yang Y4, Du F5, Ma Y1, Zhang J1 
1China Health Insurance Research Association, Beijing, China, 2Eli Lilly and Company, 
Indianapolis, IN, USA, 3Lilly Suzhou Pharmaceutical Co., Ltd. Shanghai Branch, Shanghai, China, 
4Eli Lilly Suzhou Pharmaceutical Co. Ltd. Shanghai Branch, Shanghai, China, 5Beijing Brainpower 
Pharma Consulting Co. Ltd., Beijing, China  
OBJECTIVES: The prevalence of osteoporosis fractures is anticipated to increase 
rapidly due to China's aging population. However, nationally representative data 
on inpatient hospital costs and length of stay (LOS) for osteoporosis fractures are 
lacking. The study was to estimate hospitalization costs, LOS, costs/day, and the 
co-pay burden among patients with osteoporosis fractures in China. METHODS: 
Data were extracted from the China Health Insurance Research Association 
claim database which includes a nationwide, cross-sectional sampling of 
inpatients from 2008-2010. The descriptive analysis included inpatients (≥50 
years) who had discharge diagnosis of fracture (vertebral, hip, non-
vertebral/non-hip(NVNH), or multiple fractures) and either had a diagnosis of 
pathological osteoporosis or osteoporosis drug treatment. Total medical costs 
and LOS were calculated and compared by Wilcoxon test within subgroups. 
RESULTS: The analysis included 830 patients (female:77.4%, mean age:73.4 
years). The medians of overall LOS and total costs were 19 days and 18587.0 RMB. 
Patients≥70 years (n=581) had greater LOS and costs than patients <70 years 
(median: 19 vs. 17 days, p<0.01; 21527.6 vs. 14748.6 RMB, p<0.01). Cost/day in 2008 
was 801.9±861.9 RMB, which increased by 74.3% in 2009 and 89.2% in 2010. Hip 
fractures had the longest LOS (22 days) and highest cost (32593.8 RMB); and were 
significantly greater than NVNH fracture (18 days, p<0.01; 17185.0 RMB, p<0.01). 
Reimbursement of costs by basic health insurance in 2008, 2009 and 2010 was 
51.8%, 54.7%, and 60.8%, respectively; while the corresponding patient co-pay 
